TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9065249

Group type: EXPERIMENTAL
Intervention: Methohexital (M)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol (P)
Number of subjects: 120
Study: 1380610

Group type: EXPERIMENTAL
Intervention: Verapamil slow-release (VSR)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine plus propranolol (N + P)
Number of subjects: 20
Study: 6359845

Group type: EXPERIMENTAL
Intervention: Diltiazem (D)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Verapamil (V)
Number of subjects: 45
Study: 31651403

Group type: EXPERIMENTAL
Intervention: Web-based self-help (Deprexis)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Active control (Web-based information about depression and depressive symptoms)
Number of subjects: 229
Study: 30285673

Group type: EXPERIMENTAL
Intervention: Laparoscopic total gastrectomy (LTG)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional open total gastrectomy (OTG)
Number of subjects: 200
Study: 26766027

Group type: EXPERIMENTAL
Intervention: BVS
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: BVS&BES
Number of subjects: 74

Group type: COMPARATOR
Intervention: EES&BES
Number of subjects: 74
Study: 25196873

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF), specific dosage and duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Corticosteroid treatment, specific dosage and duration not mentioned
Number of subjects: 0
Study: 21898022

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Electrocautery
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cigarette smoke
Number of subjects: 10

Group type: COMPARATOR
Intervention: Urban city air
Number of subjects: 10
Study: 19423613

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 138
Study: 18061712

Group type: EXPERIMENTAL
Intervention: Diclofenac 50 mg
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 15692468

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1% applied twice daily for 2 years
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 91
Study: 11849199

Group type: EXPERIMENTAL
Intervention: Carboplatin on course 2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cisplatin on course 2
Number of subjects: 15

Group type: COMPARATOR
Intervention: In vitro carboplatin and cisplatin (10‐100 microm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Human liver microsomes
Number of subjects: 15
Study: 9925131

Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio of 60:40
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio of 40:60
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Formula with whey-to-casein ratio of 20:80
Number of subjects: 17

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 17
Study: 7758229

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 12 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 18 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 38
Study: 2139340

Group type: EXPERIMENTAL
Intervention: Xamoterol 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Xamoterol 100, 200, or 300 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Xamoterol (various doses)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 7000149

Group type: EXPERIMENTAL
Intervention: i.v. BCG immunotherapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: i.v. BCG
Number of subjects: 182

Group type: COMPARATOR
Intervention: Irradiated leukaemic blast cells
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Immunotherapy (both groups)
Number of subjects: 182
Study: 30741563

Group type: EXPERIMENTAL
Intervention: DPA SF‐8
Number of subjects: 1380

Group type: EXPERIMENTAL
Intervention: DPA SF‐10
Number of subjects: 1380

Group type: COMPARATOR
Intervention: Original DPA scale
Number of subjects: 1380
Study: 27250634

Group type: EXPERIMENTAL
Intervention: Multimorbidity (high baseline multimorbidity score)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Work functioning trajectories (increasing, low, medium, high scores)
Number of subjects: 156
Study: 27697801

Group type: EXPERIMENTAL
Intervention: ivabradine 7.5 mg twice per day
Number of subjects: 80

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study: 24773830

Group type: EXPERIMENTAL
Intervention: OM-85 (7 mg, one daily capsule taken orally for 10 days each month for 3 consecutive months)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 244
Study: 22676715

Group type: EXPERIMENTAL
Intervention: PDX/GOS (4 g/L prebiotic blend of polydextrose and galactooligosaccharides)
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: GOS (4 g/L galactooligosaccharides)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Control (Enfamil® LIPIL®)
Number of subjects: 419
Study: 19638976

Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (UFT) with tamoxifen (TAM) for 2 years
Number of subjects: 377

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, fluorouracil (CMF) with tamoxifen (TAM) for 6 cycles
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Uracil-tegafur (UFT)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, fluorouracil (CMF)
Number of subjects: 377
Study: 17685197

Group type: EXPERIMENTAL
Intervention: Hamilton for anxiety (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: DSM‐IV for depression (n = 50)
Number of subjects: 100
Study: 16335040

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel (Perfect Bleach)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 16% carbamide peroxide bleaching gel (Viva Style)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5.3% hydrogen peroxide whitening strips (Crest Whitestrips)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 14% hydrogen peroxide whitening strips (Crest Whitestrips Supreme)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 60
Study: 11995742

Group type: EXPERIMENTAL
Intervention: Adult day care center (experimental group)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 212
Study: 10403690

Group type: EXPERIMENTAL
Intervention: Supportive care plus combination chemotherapy (IEP regimen: ifosfamide 3 gm/m2 IV with mesna uroprotection, epirubicin 60 mg/m2 IV on day 1 and cisplatin 60 mg/m2 IV on day 2)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Supportive care plus combination chemotherapy (MVP regimen: mitomycin-C 8 mg/m2, cisplatin 100 mg/m2 IV on day 1, vinblastine 4 mg/m2 IV on days 1 and 15)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 287
Study: 7720887

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy and doxorubicin‐based chemotherapy with tamoxifen
Number of subjects: 61

Group type: COMPARATOR
Intervention: Postoperative radiotherapy and doxorubicin‐based chemotherapy without tamoxifen
Number of subjects: 61
Study: 2048589

Group type: EXPERIMENTAL
Intervention: Resistance index
Number of subjects: 350

Group type: COMPARATOR
Intervention: Systolic/diastolic ratio
Number of subjects: 350

Group type: COMPARATOR
Intervention: Pulsatility index
Number of subjects: 350

Group type: COMPARATOR
Intervention: Diastolic average ratio
Number of subjects: 350
Study: 7239725

Group type: EXPERIMENTAL
Intervention: Anchor sleep taken at the same time each day (00.00-04.00; 04.00-08.00; 08.00-12.00 or 12.00-16.00) with irregular other sleep periods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Irregular sleeping routines (single randomly-timed 8-hour sleep or two randomly-arranged 4-hour sleep periods)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (irregular sleep without anchor sleep)
Number of subjects: 0
Study: 30896819

Group type: EXPERIMENTAL
Intervention: Five-lncRNA signature (DIAPH2 antisense RNA 1, FOXN3 antisense RNA 2, long intergenic non-protein coding RNA 652, maternally expressed 3, RHPN1 antisense RNA 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risk scoring system based on prognostic lncRNAs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: KEGG pathway analysis of target genes of the five prognostic lncRNAs
Number of subjects: 0
Study: 30701884

Group type: EXPERIMENTAL
Intervention: Canakinumab (monoclonal antibodies to IL-1β)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26585409

Group type: EXPERIMENTAL
Intervention: Antipsychotic review
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Antipsychotic review plus social interaction intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antipsychotic review without social intervention
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Social interaction intervention
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 16

Group type: COMPARATOR
Intervention: All interventions
Number of subjects: 16
Study: 24686347

Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (8 mm Hg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard-pressure pneumoperitoneum (12 mm Hg)
Number of subjects: 43
Study: 22309001

Group type: COMPARATOR
Intervention: Knows race only
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Knows education only
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Knows race and education
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Knows neither
Number of subjects: 71
Study: 19438740

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sham acupuncture (Group 1)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sham acupuncture (Group 2)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 175
Study: 18161400

Group type: EXPERIMENTAL
Intervention: Etoricoxib, 120 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mefenamic acid, 500 mg every 8 hours
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 14691441

Group type: EXPERIMENTAL
Intervention: Sotalol (1.5mg/kg infused in 10 minutes)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Amiodarone (10mg/kg infused in 30 minutes)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Digoxin (500 microg infused in 20 minutes)
Number of subjects: 140
Study: 11835692

Group type: EXPERIMENTAL
Intervention: Joint tele-consultation
Number of subjects: 2094

Group type: COMPARATOR
Intervention: Routine outpatient appointment
Number of subjects: 2094
Study: 11327625

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hyperglycemic subjects (HbA1c ≥ 6.0%)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 60
Study: 9040452

Group type: EXPERIMENTAL
Intervention: Reserpine (0.1 mg) plus thiazide clopamid (5 mg)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Reserpine (0.1 mg)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Thiazide clopamid (5 mg)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Nitrendipine (20 mg)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 273
Study: 8174419

Group type: EXPERIMENTAL
Intervention: fedotozine 30 mg three times a day
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: fedotozine 30 mg and 70 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: fedotozine (all doses)
Number of subjects: 146
Study: 3217992

Group type: EXPERIMENTAL
Intervention: Cisplatin (P) 60 mg/m2/day on days 1 and 2 every 28 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: CAP (cyclophosphamide 750 mg/m2, adriamycin 50 mg/m2, cisplatin 50 mg/m2 on day 1 every 21 days)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cisplatin (P)
Number of subjects: 44

Group type: COMPARATOR
Intervention: CAP
Number of subjects: 44
Study: 1567662

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 265
Study: 900585

Group type: EXPERIMENTAL
Intervention: Fenoterol metered-dose inhaler
Number of subjects: 30

Group type: COMPARATOR
Intervention: Isoproterenol metered-dose inhaler
Number of subjects: 30
Study: 30926293

Group type: EXPERIMENTAL
Intervention: Topical vibratory stimulation (100-Hz vibration applied to the popliteal fossa for 3 to 5 seconds prior to and during TPI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no vibration applied)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Topical vibratory stimulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 30081451

Group type: EXPERIMENTAL
Intervention: six-month lunch provision
Number of subjects: 223
Study: 26062925

Group type: EXPERIMENTAL
Intervention: Enhanced-CT
Number of subjects: 138

Group type: COMPARATOR
Intervention: EDUC
Number of subjects: 138
Study: 23629815

Group type: EXPERIMENTAL
Intervention: Positive emotional expression
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Negative emotional expression
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Wandering behavior
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Cognitive status
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Age, education, gender, facility type, mobility, time of day
Number of subjects: 142
Study: 21814736

Group type: EXPERIMENTAL
Intervention: Active red LLLT (660 nm, 50 mW, 17.85 W/cm², 100 s irradiation per point, 5 J, total 20 J irradiated per muscle)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active infrared LLLT (830 nm, 50 mW, 17.85 W/cm², 100 s irradiation per point, 5 J, total 20 J irradiated per muscle)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo LLLT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active red LLLT (660 nm)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Active infrared LLLT (830 nm)
Number of subjects: 10
Study: 19829284

Group type: EXPERIMENTAL
Intervention: Fibre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antispasmodics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5-HT4 agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-diarrheal agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lubiprostone
Number of subjects: 0
Study: 17992639

Group type: EXPERIMENTAL
Intervention: vildagliptin
Number of subjects: 55

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study: 15919319

Group type: EXPERIMENTAL
Intervention: Continuous infusion of ropivacaine 0.5% (0.1 mL/kg(‐1)/h(‐1)) in thoracic paravertebral block (TPVB) group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Systemic analgesia with ketoprofen, paracetamol, and PCA with intravenous morphine (control group)
Number of subjects: 40
Study: 11991693

Group type: EXPERIMENTAL
Intervention: Continuous polyamide sutures (Ethilon)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Metallic skin staples
Number of subjects: 170
Study: 10086938

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for three years
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (Down's syndrome children not receiving GH)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 15
Study: 7551664

Group type: EXPERIMENTAL
Intervention: Steroid injection without washout
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Joint washout with normal saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Joint washout with normal saline and steroid injection
Number of subjects: 60

Group type: COMPARATOR
Intervention: Joint washout alone
Number of subjects: 60
Study: 2189077

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enalapril (increased dosage from 10 to 20 mg daily in 12 patients)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Enalapril (with additional antihypertensive agents in 8 patients)
Number of subjects: 44
Study: 379093

Group type: EXPERIMENTAL
Intervention: 33% sodium fluoride paste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham burnishing with placebo paste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulus method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cold air stimulus method
Number of subjects: 0
Study: 31009419

Group type: EXPERIMENTAL
Intervention: 5% lidocaine plaster (LP5)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 36
Study: 28378156

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional debridement (Control)
Number of subjects: 0
Study: 26451863

Group type: EXPERIMENTAL
Intervention: TLIF in segment L IV/V (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TLIF in segment L V/S I (group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: TLIF in both segments
Number of subjects: 60
Study: 23593620

Group type: COMPARATOR
Intervention: ABBM alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABBM + rhPDGF
Number of subjects: 24
Study: 21233500

Group type: EXPERIMENTAL
Intervention: Dual closed-loop administration of propofol and remifentanil
Number of subjects: 196

Group type: COMPARATOR
Intervention: Manual administration of propofol and remifentanil
Number of subjects: 196
Study: 19407307

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated standard anatomical stem
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite‐coated customised stem
Number of subjects: 12
Study: 17324764

Group type: EXPERIMENTAL
Intervention: Subfascial ligation at three different levels
Number of subjects: 84

Group type: COMPARATOR
Intervention: Partial exeresis of the short saphenous vein
Number of subjects: 84
Study: 15608388

Group type: EXPERIMENTAL
Intervention: Kawasaki disease
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acute febrile illnesses
Number of subjects: 56

Group type: COMPARATOR
Intervention: Henoch-Schönlein purpura
Number of subjects: 56
Study: 12390612

Group type: COMPARATOR
Intervention: Placebo (10 mL of normal saline, 0.9% intravenously)
Number of subjects: 0
Study: 9795856

Group type: EXPERIMENTAL
Intervention: Proxymetacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amethocaine
Number of subjects: 40
Study: 7541859

Group type: EXPERIMENTAL
Intervention: Androgen deprivation (leuprolide acetate depot and flutamide) for 3 months before radical prostatectomy
Number of subjects: 287

Group type: COMPARATOR
Intervention: Surgery alone (radical prostatectomy without preoperative androgen deprivation)
Number of subjects: 287
Study: 2565117

Group type: EXPERIMENTAL
Intervention: Timolol 0.25%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metipranolol 0.3%
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metipranolol 0.1%
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 8
Study: 769156

Group type: EXPERIMENTAL
Intervention: Metiamide (Histamine H2-receptor antagonist)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Metiamide
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30968986

Group type: EXPERIMENTAL
Intervention: ParActin® 300 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: ParActin® 600 mg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 28856913

Group type: EXPERIMENTAL
Intervention: Real external transcutaneous nerve stimulation (60 Hz, 16 mA, 20 minutes)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham external transcutaneous nerve stimulation (2 mA)
Number of subjects: 38
Study: 27047398

Group type: EXPERIMENTAL
Intervention: Meditative movement exercises (MM) over a 16-week period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 20
Study: 24799326

Group type: EXPERIMENTAL
Intervention: Tolevamer 9 g (loading dose) followed by 3 g every 8 hours for 14 days
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Metronidazole 375 mg every 6 hours for 10 days
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Vancomycin 125 mg every 6 hours for 10 days
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Metronidazole in patients with severe CDI
Number of subjects: 1118
Study: 22354306

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Clindamycin (CLI)
Number of subjects: 71
Study: 21365840

Group type: EXPERIMENTAL
Intervention: 0.5 mL triamcinolone acetonide plus 0.5 mL saline (experimental group, n = 46)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1 mL saline solution (control group, n = 44)
Number of subjects: 90
Study: 17562269

Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracoscopic Surgery (VATS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Minimal Incision Thoracotomy (MIT)
Number of subjects: 32
Study: 15808038

Group type: EXPERIMENTAL
Intervention: 60 mg prednisone orally for 1 or 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Identical placebo treatment
Number of subjects: 0
Study: 11973198

Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway (COPA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 33
Study: 9616530

Group type: EXPERIMENTAL
Intervention: Intensive education (77 patients, visits every third month)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conventional education (80 patients, advice at baseline only)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 162